Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Prostatype Genomics’ long-term study with Uppsala University Hospital will be presented at the AUA conference in the US in May 2024

Prostatype Genomics announces that the interim results from the long-term follow-up study with the genetic test Prostatype®, which is conducted by and in collaboration with Uppsala University Hospital, has been accepted for presentation at the annual AUA (American Urological Association) conference in the United States in May 2024. To be accepted for presentation at this leading urology conference in the world’s largest market for prostate cancer diagnostics and prediction shows that there is a substantial interest for the study and the clinical potential of Prostatype® among American

BioStock: Medivir's CEO comments on the latest developments

As Medivir reports its fourth quarter, the company’s focus is on the further improved clinical efficacy of fostrox in combination with Lenvima in liver cancer. After recently having strengthened the cash position by more than 140 million SEK, now the aim is to accelerate the initiation of a pivotal phase IIb study and apply for accelerated approval from the FDA. BioStock reached out to CEO Jens Lindberg for a comment.Read the full interview with Jens Lindberg at biostock.se: https://www.biostock.se/en/2024/02/medivirs-ceo-comments-on-the-latest-developments/ This is a press release

Bio-Works publishes year end report for January-December 2023

A challenging year for biotech and for Bio-Works July – December 2023 · Net sales decreased by 6% to 21.8 (23.2) MSEK. Sales in Europe continued to be strong in the second half as a result of orders made prior to the period. The economic slow-down in North America had a negative impact on sales in the period. · Order intake* decreased by 70% to 10.2 (34.3) MSEK. The economic slow-down in our main markets has made some of our customers delay production and investments in new projects. The distribution of orders over Q3 and Q4 was 2.8 MSEK and 7.4 MSEK, respectively. · Profit in

BioStock: Full speed ahead for Elicera in 2024

Elicera Therapeutics has kicked off the year in boost mode. The Swedish cell and gene therapy company will get moving on the newly approved phase I/IIa study with lead CAR T candidate ELC-301, made possible by a major financing round coming later this month. Speaking to Elicera’s CEO Jamal El-Mosleh, it’s clear that the company is ready for a busy 2024, where now two pipeline candidates are in the clinic.Read the full interview with Jamal El-Mosleh at biostock.se: https://www.biostock.se/en/2024/02/full-speed-ahead-for-elicera-in-2024/ This is a press release from BioStock -

Buybacks of shares in ITAB during week 7 2024

During the period between 12 and 16 February 2024, ITAB Shop Concept AB (publ) (”ITAB”) (LEI-code: 2138001H6FCSZBP26351) has repurchased in total 273,763 own ordinary shares (ISIN: SE0015962097) as part of the share buyback program initiated by the Board of Directors in order to optimise the capital structure.The share buybacks form part of the share buyback program in a maximum amount of MSEK 50 that ITAB announced on 28 September 2023. The share buyback program, which runs from 29 September 2023 until 14 May 2024, is being carried out in accordance with the EU Market Abuse Regulation (“

COSEL launches enhanced reliability power supplies for industrial applications

•    Low component count for extended reliability•    For system’s upgrade - Form-Fit Function 100% compatible with the PBA series•    Safety approvals UL62368-1, c-UL (equivalent to CAN/CSA-22.2 No.62368-1), EN62368-1•    Wide operating temperature range -20 to +70 degrees C•    High reliability – 5-year warranty COSEL Co, Ltd (6905: Tokyo) has announced the launch of the PDA series  of AC/DC power supplies with further enhanced reliability for industrial applications. In order to offer the highest price/performance ratio while

University of Saarland chooses Sectra Education Portal to bridge the gap to clinical reality for radiographer students

Linköping, Sweden – February 19, 2024 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) will provide the University of Saarland with its platform for medical education—Sectra Education Portal. The platform provides real-life clinical cases, which will enhance the educational experiences for radiographer students, as well as elevate self-directed learning and remote studies. By adding Sectra’s solution for medical education to their existing Sectra enterprise imaging solution, they are bridging the gap between education and the clinical

Valmet’s share buy-back program for its share-based incentive plans has ended

Valmet’s share buy-back program for its share-based incentive plans has ended Valmet Oyj’s press release on February 19, 2024 at 9:30 a.m. EET   Valmet has now completed the share buy-back program for its share-based incentive plans. The acquisitions of the own shares began on February 12, 2024, and ended on February 16, 2024. During that period, Valmet acquired in aggregate 100,000 of its own shares for an average price per share of EUR 25.58. The total purchase price paid for the shares was EUR 2,557,818. The shares were acquired at market price in public trading on Nasdaq

Wulff Group Plc’s Financial Statements Release January 1 – December 31, 2023

FINANCIAL STATEMENTS RELEASE | FEBRUARY 19, 2024 AT 9.30 A.M. This is a summary of Wulff Group Plc’s Financial Statements Release January 1–December 31, 2023. The complete report is attached to this stock exchange release as a pdf-file. The report is also available at the website www.wulff.fi Positive profitability development in Q4, a proposal for a growing dividend 1.10.-31.12.2023 BRIEFLY · Net sales decreased by 17.1% and totalled EUR 22.9 million (27.7) · EBITDA was EUR 1.6 million (1.8), and comparable EBITDA was EUR 1.6 million (1.8) · Operating profit (EBIT) was

Continued demand for Quartzene[®] in cool roof paint – Svenska Aerogel receives 3 ton order

Svenska Aerogel receives a call-off order for 3 tons of Quartzene[®] from its French distributor Novcoat. The order thus represents a delivery contract between the two companies for 2024 and will be divided into four deliveries during the year. The material will be used by Novcoat’s customer in cool roof paint.When planning its deliveries for 2024, Novcoat’s customer ordered a total of 3 tons of Quartzene®. The value of the order is 96.8 KEUR.   Tor Einar Norbakk, CEO of Svenska Aerogel, comments: ”This order is a very positive sign for us, as it indicates continued strong growth for

BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise

Last year, a lot of focus for Curasight revolved around prostate cancer and the licensing deal with Curium. Now, the company has announced the next step for the theranostic approach and its wish to accelerate clinical development of both uTREAT and uTRACE in parallel. Curasight aims at starting a phase I/IIa basket trial in several indications and in order to finance this updated develoment strategy, the company aims at raising DKK 51.2 million in a rights issue. BioStock contacted CEO Ulrich Krasilnikoff to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2024/

Tagrisso plus chemo approved in US for lung cancer

19 February 2024 Tagrisso with the addition of chemotherapy approved in the  US for patients with EGFR-mutated advanced lung cancer Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care AstraZeneca's Tagrisso (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval following a Priority

Notice convening YIT Corporation’s Annual General Meeting

YIT Corporation Stock Exchange Release 19 February 2024 at 09:10 a.m.Notice convening YIT Corporation’s Annual General Meeting The shareholders of YIT Corporation are invited to attend the Annual General Meeting to be held on Thursday,14 March 2024, starting at 11:00 a.m. Finnish time (GMT+2) in Messukeskus Siipi, located at the address Rautatieläisenkatu 3, 00520 Helsinki, Finland. Check-in for those who have registered for the meeting, the distribution of voting tickets and coffee service will start at the meeting venue at 10:00 a.m. Finnish time. Shareholders may also exercise

Invitation to Fourth Quarter 2023 Results

Oslo, 19 February 2024: BlueNord ASA ("BlueNord" or the "Company") will publish its financial results for the fourth quarter of 2023 on Tuesday 20 February 2024 at 07:00 (CET). A webcast presentation, followed by a Q&A session, will be hosted at 10:00 (CET). To join webcast: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240220_4 *** Contact: Cathrine Torgersen, Chief Corporate Affairs OfficerEmail: cathrine.torgersen@bluenord.comPhone: +47 915 28 501

FDA accepts Dato-DXd BLA for nonsquamous NSCLC

19 February 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer Application based on results from the TROPION-Lung01 Phase III trial If approved, AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan may bethe first TROP2-directed antibody drug conjugate for patients with lung cancer AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally

Nordic Mining ASA: Key information relating to the reverse split

Date on which the corporate action was made public: 19 February 2024 Reverse split ratio: 20 old shares give 1 new share Last day including right: 12 March 2024 Ex-date: 13 March 2024 Record date: 14 March 2024 Date of approval: 11 March 2024 A new ISIN number will be issued for the new shares: NO0013162693 Other information: The reverse split is subject to approval by the extraordinary general meeting on 11 March 2024. For further information, please contact CFO Jens Gisle Schnelle, telephone +47 476 60 355 Oslo, 19 February 2024Nordic Mining ASA This

Tagrisso improved PFS in Stage III lung cancer

19 February 2024 Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting Positive high-level results from the LAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (

Metso to deliver key crushing and grinding technology to the Hemi Gold Project in Australia

Metso Corporation’s press release on February 19, 2024, at 09:00 a.m. EETAustralian mining company De Grey Mining Limited has awarded Metso orders for a Superior™ MKIII 50-65 primary gyratory crusher and two 14MW Premier™ ball mills. The equipment will be installed at De Grey Mining’s Hemi Gold Project located in the Pilbara region of Western Australia. The combined order value of over EUR 20 million is booked in the Minerals segment’s first-quarter 2024 orders received.  “Our aim with the Hemi Gold Project is to deliver a Tier 1 gold project and make a future top 5 Australian Gold Mine

Nitro Games Oyj: Year-end report January – December 2023

REPORTING PERIOD JANUARY – DECEMBER 2023 · Revenues 8,841.6 KEUR (7,247.9 KEUR). · EBITDA: -1,716.6 KEUR (-2,799.8 KEUR). · EBIT: -3,024.8 KEUR (-3,621.3 KEUR). · Net result: -3,283.1 KEUR (-3,707.6 KEUR). · Earnings per share (EPS) -0.19 (-0.29). · Cash and cash equivalents: 3,825.8 KEUR and 1,199.7 KEUR of short-term receivables (31 December 2023). (All figures are presented in accordance with IFRS and, unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year.) OCTOBER – DECEMBER 2023 · Revenues 2,894.

Nordic Mining ASA: Summons to Extraordinary General Meeting - Reverse Split

Shareholders in Nordic Mining ASA are invited to attend the Extraordinary General Meeting held on Monday 11 March 2024 at 10:00 CET. The general meeting will be held as a virtual meeting, where shareholders will be able to participate electronically via PC, phone or tablet. The Board of Directors proposes that the general meeting resolves a reverse share split in the ratio 20:1, so that 20 shares are consolidated into 1. It is proposed that the Board of Directors is authorized to determine the date and the further process for completion of the reverse share split. Expected dates,

Transaction in Own Shares

    19 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |16/02/2024|+----------------------------------------------------------

The Nomination Committee’s proposal to the Annual General Meeting 2024

STOCKHOLM, February 19[th], 2024. Moberg Pharma AB (OMX: MOB) announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2024.The Nomination CommitteeThe Nomination Committee consists of the Chairman Gillis Cullin representing Östersjöstiftelsen and the members Ida Marie Lindberg, representing Kjelsmark Holding and Kerstin Valinder Strinnholm, Chairman of the Board of Directors in the Company. Chairman of the Annual General MeetingThe Nomination Committee proposes that Kerstin Valinder Strinnholm is elected as

Notice to Extraordinary General Meeting of Kindred Group plc

Kindred Group plc NOTICE IS HEREBY GIVEN that THE EXTRAORDINARY GENERAL MEETING (“EGM”) of Kindred Group plc (C 39017) (the “Company”) convened in terms of article 135 (1)(b) of the Companies Act (Cap. 386 of the Laws of Malta) will be held on Friday 15 March 2024 at 10:00 am CET at Kindred’s office, Regeringsgatan 25, Stockholm, Sweden.Notice to holders of Swedish Depository Receipts (“SDRs”) Holders of SDRs who wish to exercise their voting right at the EGM must: (i) be registered in the register kept by Euroclear Sweden AB by Tuesday 5 March 2024 (the “Record Date”); and (ii)

There are no items matching the current filter
There are no more items matching the current filter
Back to top